https://doi.org/10.55788/1b6afe9c
PCSK9 inhibitors can reduce LDL-C, even in patients that cannot reach ideal LDL-C target levels with high-dose statin and ezetimibe. They have also been shown to reduce MACE [1]. However, it remained unclear whether potential sex differences in LDL-C reduction existed. Dr Frederick Rivera (Lincoln Medical Center, NY, USA) and colleagues hence performed a comprehensive literature search, identifying ongoing studies using ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform [2]. Included in the meta-analysis were 16 trials that passed the inclusion criteria.
Adverse cardiovascular outcomes were significantly reduced by PCSK9 inhibitor use versus placebo in both men (HR 0.85; 95% CI 0.80â0.91; P<0.0001) and women (HR 0.86; 95% CI 0.76â0.96; P=0.009). The significant reductions in LDL-C that were found with PCSK9 inhibitors compared with placebo and ezetimibe were similar for both sexes. A significant reduction in LDL-C was seen in both sexes when analysed according to the frequency of PCSK9 inhibitor administration (i.e. biweekly or monthly) and the type of PCSK9 inhibitor (i.e. evolocumab or alirocumab).
âWe conclude that there is no sex difference regarding adverse cardiovascular events and LDL-C reduction among PCSK9 inhibitors. However, subgroup analysis shows greater LDL-C-lowering in men compared with women,â Dr Rivera said.
- Du H, et al. Heart 2019;105(15):1149â1159.
- Rivera FB, et al. Sex Differences on cardiovascular outcomes of Pcsk9-inhibitors: A meta-analysis. GR.APS.P201, AHA Scientific Sessions 2022, 05â07 November, Chicago, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« ‘Noâ to routine use of rivaroxaban in outpatients with COVID-19 Next Article
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged »
« ‘Noâ to routine use of rivaroxaban in outpatients with COVID-19 Next Article
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged »
Table of Contents: AHA 2022
Featured articles
What Is New in Heart Failure
Torsemide not superior to furosemide after hospitalisation for heart failure
IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients
Up-titration of HF therapies following HF discharge saves lives
Hypertension: Novel Developments
The endothelin system: a new target for resistant high blood pressure
Can renal denervation lower BP on top of antihypertensive drugs?
Quadruple, ultra-low-dose treatment did not meet primary endpoint in hypertension
Mindfulness programme contributes to office blood pressure lowering
Interventional Cardiology in 2022
Grafting with the radial vein: an underrated option in CABG surgery?
Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock
Surgery with adequate saphenous vein partly better than endovascular treatment in CLTI
Arrhythmia â State of the Art
First-line ablation limits progression to persistent AF
Doubling the dose of self-administered etripamil terminates PSVT
Novel Developments in Primary and Secondary Prevention
Grafting with the radial vein: an underrated option in CABG surgery?
Digitally delivered cognitive behavioural therapy successful in type 2 diabetes
Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD
RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged
No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors
COVID-19 and the Heart
‘Noâ to routine use of rivaroxaban in outpatients with COVID-19
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality
COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation
Best of the Posters
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly
AF: Moderate alcohol intake possibly associated with a reduced mortality risk
Periodontitis: An independent risk factor for AF
Related Articles
January 11, 2023
Doubling the dose of self-administered etripamil terminates PSVT
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com